Tarsa Therapeutics announced positive results from its Phase 3 ORACAL study of oral recombinant salmon calcitonin for the treatment of postmenopausal osteoporosis. The multinational, randomized, double-blind, double-dummy, placebo-controlled trial compared oral recombinant salmon calcitonin with synthetic salmon calcitonin administered by nasal spray in 565 postmenopausal women with osteoporosis. Data showed oral salmon calcitonin to be statistically significantly noninferior to nasal salmon calcitonin and superior to placebo in increasing bone mineral density at the lumbar spine after one year.
Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland. Studies have shown that calcitonin-salmon causes inhibition of osteoclast function with loss of the ruffled osteoclast border responsible for bone resorption.
For more information call (267) 273-7940 or visit www.tarsatherapeutics.com.